New combo therapy aims to tackle returning lymphoma
NCT ID NCT02446457
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether combining rituximab and pembrolizumab, with or without lenalidomide, can help patients with follicular lymphoma or diffuse large B-cell lymphoma that has returned after previous treatment. The study enrolls 53 participants and measures how many patients achieve a complete or partial response. The goal is to find a more effective treatment for these relapsed cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab, pembrolizumab, and lenalidomide
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with relapsed follicular lymphoma or diffuse large B-cell lymphoma, potentially improving response rates.
- What could go wrong
- This is an early-phase trial with a small number of participants (53). The treatment may cause side effects, and not all patients may respond. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New combo attack on lymphoma shows promise in early trial
- Engineered immune cells target lymphoma after transplant